Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014

Previous Page: Conclusion

Appendix

Key Questions Reviewed by the Work Group and Member(s) Responsible for Literature Summary


Performance Characteristics

  • Does the sensitivity and specificity of available tests for C. trachomatis and N. gonorrhoeae vary with respect to anatomic site from which the specimen was collected and/or specimen type?
    • Joan Chow, DrPH, California Department of Public Health, Richmond, California
    • Katherine Whitaker, PhD, Food and Drug Administration, Rockville, Maryland
  • What recommendations should be made for the detection of C. trachomatis and N. gonorrhoeae infections of the genital tract, rectum, and throat?
    • Gary Budnick, MHS, Connecticut Department of Public Health Laboratory, Hartford, Connecticut
    • Steven Shapiro, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
    • Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota
  • What test recommendations should be made for the diagnosis of suspected LGV infections (inguinal and rectal presentations)?
    • Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Screening Applications

  • What specimen types are optimal for of C. trachomatis and N. gonorrhoeae screening purposes?
    • Charlotte Gaydos, DrPH, Johns Hopkins University, Baltimore, Maryland
    • Sarah Guerry, MD, Los Angeles County Department of Health Services, Los Angeles, California
    • Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana
  • What parameters should be considered when selecting a C. trachomatis and N. gonorrhoeae test for screening purposes?
    • George Dizikes, PhD, Illinois Department of Public Health, Chicago, Illinois
    • Robert E Johnson, MD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
    • Scott Zimmerman, DrPH, Erie County Public Health Laboratory, Buffalo, New York

Economic Considerations

  • What economic considerations might influence laboratory testing?
    • Thomas Gift, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Laboratory Confirmation

  • What approaches, if any, can be used to derive a definitive laboratory confirmation of C. trachomatis and N. gonorrhoeae?
    • Yetunde Fakile, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
    • Dennis Ferrero, MPH, Department of Biological Sciences, University of the Pacific, Stockton, California
    • Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota
    • Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana

Work Group Members
As of January 2009


Chair:
John R. Papp, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia.

Presenters: Gary Budnick, MHS, Connecticut Department of Public Health Laboratory, Hartford, Connecticut; Joan Chow, DrPH, California Department of Public Health, Richmond, California; George Dizikes, PhD, Illinois Department of Public Health, Chicago, Illinois; Dennis Ferrero, MPH, Department of Biological Sciences, University of the Pacific, Stockton, California; Charlotte Gaydos, DrPH, Johns Hopkins University, Baltimore, Maryland; Sarah Guerry, MD, Los Angeles County Department of Health Services, Los Angeles, California; Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota; Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana; Katherine Whitaker, PhD, Food and Drug Administration, Rockville, Maryland; Scott Zimmerman, DrPH, Erie County Public Health Laboratory, Buffalo, New York; Yetunde Fakile, PhD, Thomas Gift, PhD, Robert E Johnson, MD, Steven Shapiro, Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia;

Consultants: Stefanie Akselrod, MS, Food and Drug Administration, Rockville, Maryland; James Beebe, PhD, San Luis Obispo County Health Agency, San Luis Obispo, California; Julius Schachter, PhD, University of California, San Francisco, California; Shari Shea, MPH, Association of Public Health Laboratories, Silver Spring, Maryland; Melissa Singer, MPH, Centers for Medicare and Medicaid Services, Baltimore, Maryland; Dean Willis, DrPH, Florida Department of Health (Retired), Jacksonville, Florida; Kimberly Workowski, MD, Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC and Emory University, Atlanta, Georgia; Kelly Wroblewski, MPH, Association of Public Health Laboratories, Silver Spring, Maryland.

 

Previous Page: Conclusion

 

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC-INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #